MX2012003208A - Agonistas de receptores de oxitocina. - Google Patents

Agonistas de receptores de oxitocina.

Info

Publication number
MX2012003208A
MX2012003208A MX2012003208A MX2012003208A MX2012003208A MX 2012003208 A MX2012003208 A MX 2012003208A MX 2012003208 A MX2012003208 A MX 2012003208A MX 2012003208 A MX2012003208 A MX 2012003208A MX 2012003208 A MX2012003208 A MX 2012003208A
Authority
MX
Mexico
Prior art keywords
compounds
oxytocin receptor
maintenance
treatment
conditions
Prior art date
Application number
MX2012003208A
Other languages
English (en)
Inventor
Robert Galyean
Kazimierz A Wisniewski
Claudio Daniel Schteingart
Sudarkodi Alagarsamy
Original Assignee
Ferring Int Ct Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Int Ct Sa filed Critical Ferring Int Ct Sa
Publication of MX2012003208A publication Critical patent/MX2012003208A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/16—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Pregnancy & Childbirth (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a compuestos agonistas de receptores de oxitocina, a composiciones farmacéuticas que comprenden los mismos, al uso de estos compuestos para la manufactura de un medicamento para el tratamiento de, inter alia, dolor abdominal, síndrome de intestino irritable (lBS), autismo, disfunción eréctil, disfunción sexual femenina, inducción y mantenimiento del trabajo de parto, inducción y mantenimiento de lactación, hemorragia posparto, Trastorno de Estrés Postraumático (PTSD), dolor, ansiedad y otras condiciones, así como también a métodos para el tratamiento de estas condiciones, en donde estos compuestos se administran. Los compuestos son representados por la fórmula general (I), como se define adicionalmente en la especificación.
MX2012003208A 2009-09-21 2010-09-21 Agonistas de receptores de oxitocina. MX2012003208A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24432709P 2009-09-21 2009-09-21
PCT/US2010/049714 WO2011035330A2 (en) 2009-09-21 2010-09-21 Oxytocin receptor agonists

Publications (1)

Publication Number Publication Date
MX2012003208A true MX2012003208A (es) 2012-05-29

Family

ID=43629442

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012003208A MX2012003208A (es) 2009-09-21 2010-09-21 Agonistas de receptores de oxitocina.

Country Status (17)

Country Link
US (1) US8748564B2 (es)
EP (1) EP2491052A2 (es)
JP (1) JP5750443B2 (es)
KR (1) KR20120093840A (es)
CN (1) CN102656183B (es)
AR (1) AR078304A1 (es)
AU (1) AU2010295294B2 (es)
BR (1) BR112012006185A2 (es)
CA (1) CA2774593C (es)
IL (1) IL218649A (es)
IN (1) IN2012DN02103A (es)
MX (1) MX2012003208A (es)
NZ (1) NZ598579A (es)
RU (1) RU2539692C2 (es)
SA (1) SA110310710B1 (es)
TW (1) TWI463990B (es)
WO (1) WO2011035330A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013139861A1 (en) 2012-03-20 2013-09-26 Luc Montagnier Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
HUE039848T2 (hu) 2012-12-21 2019-02-28 Hoffmann La Roche Peptidek oxitocin agonistákként
EA030091B1 (ru) * 2014-06-03 2018-06-29 Ф. Хоффманн-Ля Рош Аг Пептиды, выполняющие роль агонистов окситоцина
CR20160562A (es) * 2014-06-06 2017-01-06 Hoffmann La Roche Péptidos como agonistas de la oxitocina
WO2016025629A1 (en) 2014-08-12 2016-02-18 The Regents Of The University Of California Molecular composition for enhancing and rejuvenating maintenance and repair of mammalian tissues
CA2957224A1 (en) 2014-09-19 2016-03-24 Ferring B.V. Method of treating prader-willi syndrome
MX2017005692A (es) 2014-10-31 2017-08-07 Glaxosmithkline Ip Dev Ltd Formulacion en polvo.
WO2017060339A1 (en) * 2015-10-06 2017-04-13 Ferring B.V. New methods for making barusiban and its intermediates
CN106967155B (zh) * 2017-03-17 2018-05-15 兰州凯博药业股份有限公司 一种多肽液相合成缩宫素的方法
WO2019032946A1 (en) 2017-08-11 2019-02-14 Ferring B.V. PROCESS FOR PRODUCING OXYTOCIN
AU2018340867B2 (en) * 2017-09-28 2021-05-27 Kinoxis Therapeutics Pty Ltd Metabolite inspired selective oxytocin receptor agonists
WO2019180269A1 (en) 2018-03-23 2019-09-26 Cytoo Alk5 inhibitors as skeletal muscle hypertrophy inducers
KR20210062648A (ko) 2018-09-20 2021-05-31 레보 테라퓨틱스 인코포레이티드 카르베토신 완제의약품 및 이를 제조하는 방법
EP3852723A4 (en) 2018-09-20 2022-06-29 Levo Therapeutics, Inc. Stable intranasal formulations of carbetocin
AU2020380587A1 (en) 2019-11-04 2022-01-06 Ferring B.V. Intranasal administration of merotocin for improving lactation
TW202304498A (zh) 2021-03-26 2023-02-01 法商Ｏｔ４Ｂ公司 吞嚥困難之治療
WO2023118303A1 (en) 2021-12-21 2023-06-29 Universitaet Wien Highly stable oxytocin derivatives

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS194980B1 (en) * 1976-07-16 1979-12-31 Joseph H Cort Agent for current induction,fertilization facilitating and milkability increasing at mammals,especially at utility cattle
SE430885B (sv) * 1980-03-24 1983-12-19 Ferring Ab Oxytocin-derivat
CS216722B1 (en) * 1980-06-24 1982-11-26 Michal Lebl Oxytocine analogues and method of making the same
US4483794A (en) * 1983-05-10 1984-11-20 Ceskoslovenska Akademie Ved Analogs of neurohypophysial hormones
SE9604341D0 (sv) * 1996-11-26 1996-11-26 Ferring Bv Hepta-peptide oxytocin analogue
WO2002058721A1 (en) * 2000-12-08 2002-08-01 Baylor College Of Medicine Trem-1 splice variant for use in modifying immune responses
ES2277640T3 (es) 2002-02-27 2007-07-16 Ferring Bv Productos intermedios y metodos para preparar analogos de heptapeptido de oxitocina.
WO2007095021A2 (en) * 2006-02-10 2007-08-23 Ferring B.V Novel compounds

Also Published As

Publication number Publication date
IL218649A0 (en) 2012-05-31
CN102656183B (zh) 2016-03-30
WO2011035330A2 (en) 2011-03-24
CN102656183A (zh) 2012-09-05
AU2010295294A1 (en) 2012-03-29
AR078304A1 (es) 2011-10-26
US20120214733A1 (en) 2012-08-23
CA2774593C (en) 2016-12-06
NZ598579A (en) 2014-02-28
EP2491052A2 (en) 2012-08-29
AU2010295294A8 (en) 2012-05-31
JP5750443B2 (ja) 2015-07-22
TW201114434A (en) 2011-05-01
JP2013505269A (ja) 2013-02-14
RU2012110349A (ru) 2013-10-27
KR20120093840A (ko) 2012-08-23
BR112012006185A2 (pt) 2016-05-31
RU2539692C2 (ru) 2015-01-27
US8748564B2 (en) 2014-06-10
TWI463990B (zh) 2014-12-11
CA2774593A1 (en) 2011-03-24
IL218649A (en) 2016-11-30
WO2011035330A4 (en) 2011-07-07
AU2010295294B2 (en) 2015-12-10
SA110310710B1 (ar) 2015-01-05
IN2012DN02103A (es) 2015-08-21
WO2011035330A3 (en) 2011-05-19

Similar Documents

Publication Publication Date Title
MX2012003208A (es) Agonistas de receptores de oxitocina.
PH12015501289B1 (en) Novel benzimidazole derivatives as ep4 antagonists
EA031157B9 (ru) Вводимая перорально кортикостероидная композиция
MY153976A (en) Lh liquid formulations
MX342161B (es) Compuestos antagonistas selectivos de receptor nk-3 novedosos, composicion farmaceutica y metodos para utilizarse en trastornos transmitidos por receptores nk-3.
PH12015501452A1 (en) Novel quinolone derivatives
EA201270492A1 (ru) Соединения для лечения дислипидемии и связанных с ней заболеваний
TN2012000534A1 (en) Pyrazole compounds as sigma receptor inhibitors
MX2014000142A (es) Uso de anticuerpos agonistas anti-cd83 para tratar enfermedades autoinmunes.
PH12014501195A1 (en) Novel 2h-indazoles as ep2, receptor antagonists
IN2014MN00697A (es)
GEP20156231B (en) Agomelatine hydrochloride hydrate and preparation there of
MX2011012669A (es) Nuevos agonistas del receptor de glucocorticoides.
PH12014501943A1 (en) Novel compounds for the treatment of dyslipidemia and related diseases
MX2014002393A (es) Inhibidores de rock suaves, novedosos.
IN2013DN02555A (es)
MX2013003736A (es) Novedosos agonistas del receptor de la proteina g 119.
IN2014KN00849A (es)
GEP20156232B (en) Agomelatine hydrochloride hydrate and preparation thereof
EP2563785A4 (en) Compounds as Agonists Against S1P1 Receptors
IN2014KN00847A (es)
FI20106293A0 (fi) Uudet farmaseuttiset koostumukset
EA201690240A1 (ru) Новые соединения индазола и способ их получения

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: FERRING B.V.

FG Grant or registration